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INTRODUCTION
Refractory and relapsed acute leukemias are characterized by an interplay of cellular mechanisms that shift the balance between cell survival and death pathways toward prolonged survival and, in turn, net drug resistance. The clinical outlook for such patients is very poor, with complete remissions (CRs) being achieved in 30% or fewer and a 1 year disease-free survival (DFS) of less than 10% with the use of current antileukemic agents. As a result, there is no standard of care for these diseases at the present time. In order to improve our results, one goal of any new therapeutic approach must be the ability to overcome drug resistance and promote druginduced cell death. This may be achieved by mechanism-based combination chemotherapy.
Clofarabine is a novel deoxyadenosine analog that is resistant to deamination by adenosine deaminase and phosphorolytic cleavage by bacterial purine nucleoside phosphorylase 1 . Clofarabine has clinical activity as a single agent and in combination with cytosine arabinoside (ara-C) against refractory and relapsed pediatric acute lymphoblastic leukemia (ALL) 2, 3 and against relapsed and poor-risk, newly diagnosed acute myelogenous leukemia (AML) in adults, including those age 50 and older [4] [5] [6] [7] [8] . Clofarabine exerts its cytotoxicity through multiple mechanisms of action, with major effect on ribonucleotide reductase (RR) inhibition 9 and incorporation into DNA followed by inhibition of DNA polymerases 10, 11 .
Additional effects on mitochondrial membrane polarization and disruption with resultant cytochrome c release and apoptosis induction have been reported 12 .
Ribonucleotide reductase (RR) converts ribonucleotides into deoxyribonucleotides and is therefore a pivotal enzyme in the processes of DNA synthesis and repair of DNA damage.
Inhibition of RR depletes the intracellular pools of deoxyribonucleotides and their triphosphorylated forms (dNTPs). The depletion enhances the intracellular accumulation of For personal use only. on June 15, 2017. by guest www.bloodjournal.org From nucleoside analogs and the incorporation of triphosphorylated nucleoside analogs into DNA, thereby heightening the cytotoxic effects of those agents.
Cyclophosphamide (Cytoxan, CY) is an alkylating agent that is effectively used for treatment of leukemias. A primary lesion of CY damage is DNA interstrand crosslinks. These crosslinks have been seen to be rapidly repaired in chronic lymphocytic leukemia (CLL) lymphocytes after in vitro exposure to activated CY 13 . However, pretreatment with clofarabine impedes completion of the repair of DNA strand breaks, with resultant increase in apoptosis.
This effect may be due to inhibition of both RR and DNA synthesis by clofarabine triphopshate (clofarabine-TP) 13 .
On the basis of these findings and rationale, we designed a Phase I clinical-laboratory correlative trial to test the hypothesis that pretreatment with clofarabine would impede the full repair of CY-induced DNA strand breaks and would therefore augment CY-driven cytotoxicity in vivo and possibly improve clinical responses in patients with relapsed or refractory acute leukemias. We delivered the drug combination in a timed sequential fashion 14, 15 . To confirm that CY-induced DNA damage was enhanced by clofarabine pretreatment, we measured leukemia cell DNA damage directly and serially during treatment. In order to test for potential augmentation of CY-induced DNA damage by clofarabine, we compared DNA damage with CY alone and with CY following clofarabine pretreatment. pregnancy test within 48 hrs prior to study, willingness to practice contraception, no more than 4 prior induction regimens (3 cytotoxic chemotherapy regimens), ineligible for established curative regimens including stem cell transplantation (SCT), and able to provide informed consent.
PATIENTS, MATERIALS AND METHODS

Patient Eligibility and Selection
Patients who were unresponsive to or had relapsed after allogeneic or autologous SCT were eligible. The interval from prior treatment was at least 3 weeks for myelosuppressive cytotoxic agents (6 weeks for mitomycin or nitrosoureas), 2 weeks for radiotherapy, and 1 week for either non-myelosuppressive treatments or treatment with hematopoietic growth factors. Hydroxyurea (HU) and/or imatininb were permitted for control of blast counts prior to clofarabine-CY therapy, but had to be discontinued > 72 hours before initiation of clofarabine-CY. All patients provided written informed consent according to the Johns Hopkins Medical Institutional Review Boards and guidelines.
Treatment Schema
This Phase I study was designed to determine the maximal tolerated dose (MTD) and assess the toxicity of clofarabine followed by fractionated CY in adults with relapsed or refractory acute leukemias. An additional objective was to test the hypothesis that clofarabine would inhibit the repair process initiated by CY-induced DNA damage. Single-agent CY was administered by 2hour intravenous (IV) infusion on Day 0 of cycle 1. On Days 1-3 and 8-10, clofarabine was administered by IV infusion 2 hours before each dose of CY. For dose level 1, the Days 0 and 1
For personal use only. on June 15, 2017. by guest www.bloodjournal.org From CY doses were 200 mg/m 2 /dose and the Days 2,3,8-10 doses were 400 mg/m 2 /dose; the clofarabine dose was 20 mg/m 2 /day days 1-3 and 8-10. Dose escalations for both clofarabine and CY were planned, with step-wise increases in clofarabine dose up to 50 mg/m 2 /dose and CY up to 800 mg/m 2 /day. However, because of dose-limiting toxicity (DLT) at dose level 1, clofarabine dosage was de-escalated for to 10 mg/m 2 /day (dose level 0).
Supportive Care
Clofarabine-Related Infusional Toxicities: Clofarabine administration has been associated with a systemic inflammatory response consisting of fever, respiratory distress, hypotension, capillary leak (pleural and pericardial effusions), and multi-organ failure 2, 3, 5, 7 . This constellation of symptoms has been most pronounced in the setting of drug-induced tumor lysis syndrome. To decrease the incidence and severity of this clofarabine-related cytokine release syndrome, all patients were premedicated with acetaminophen 650 -1000 mg orally 30 minutes prior to each dose of clofarabine to minimize the risk of fever and received prophylactic steroids (hydrocortisone 100 mg daily) on Days 1, 2, and 3 prior to clofarabine dosing. Histamine (H1 and H2) blockade was also administered to patients with evidence of systemic inflammatory response syndrome or cytokine release manifested as tachypnea, tachycardia, fever, or hypotension temporally associated with clofarabine infusions.
Allopurinol: All patients without known allergy to allopurinol received allopurinol 300 mg/day days 0 through 5 to prevent occurrence and complications of tumor lysis-induced hyperuricemia. 
Response and Toxicity Evaluation
To assess response to therapy, bone marrow aspiration and biopsy were performed prior to treatment, on day 14, and at the time of hematologic recovery or when leukemia regrowth was suspected clinically. Hematologic recovery was defined as absolute neutrophil count (ANC) > 500/mm 3 and a transfusion-independent platelet count > 50,000/mm 3 . CR required a normal bone marrow aspirate with absence of identifiable leukemia, absence of peripheral blood blasts, ANC > 1000/mm 3 , platelet count >100,000/mm 3 and clearance of extramedullary disease including splenomegaly. Clearance of cytogenetic abnormalities was not required for CR, but was noted and described separately. Partial remission (PR) was defined as trilineage hematopoiesis in the marrow with normalization of peripheral blood counts but with 5-25% blasts in the marrow, ≥ 50% decrease in bone marrow blasts, or persistent splenomegaly. Response criteria for acute leukemias are consistent with those published by Cheson, et al 16 . Responses were determined following the first cycle of clofarabine-CY.
The NCI Common Toxicity Criteria, version 3.0, was the basis upon which all adverse events were described and graded, based on the treating physician's assessment. Dose limiting toxicity (DLT) was based on toxicities incurred during the first treatment cycle. If 2/3 or 2/6 patients developed DLT, the MTD was defined as one dose level below which the DLTs were observed. If 2/3 or 2/6 patients at dose level 1 experienced DLT, the dose of clofarabine was reduced to 10 mg/m 2 /day with the CY dose remaining constant. Myelosuppression was not considered in evaluating toxicity except where bone marrow hypoplasia persisted for ≥ 42 days with marrow cellularity ≤ 5% and no evidence of leukemia. Myelosuppression-related DLT occurred when ANC did not return to 1000/µL and platelets did not return to 75,000/µL or 20% of baseline values (whichever was less) by Day 42 of therapy.
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Laboratory Correlates
All studies of peripheral blood and bone marrow blast populations were conducted following blast enrichment by Ficoll density separation. For the 13 patients whose circulating blasts were analyzed longitudinally for DNA damage and apoptosis, the median percentage of blasts prior to Ficoll enrichment was 75% (range 31-96) on Day 0 prior to treatment and 68% (range 29-100%) on Day 1 after CY alone and before beginning the clofarabine infusion. The minimal percentage of blasts following Ficoll enrichment was 70% for all specimens.
Measurement of DNA Damage
Histone H2AX is phosphorylated in response to the presence of DNA double strand breaks 15 . As such, the presence and magnitude of phosphorylated H2AX (γH2AX) is an indication of persistent, unrepaired DNA damage 18 . We measured DNA damage by flow cytometry of leukemia blasts stained with antibody to γ H2AX 18, 19 . Peripheral blood blasts were sampled before treatment, at the completion of Day 0 CY infusion, 2 hours after completion of Day 0 CY infusion, and 2 hours after completion of the combination of clofarabine followed by CY on Day 1. When feasible, bone marrow blasts were assayed for the presence and magnitude of γ H2AX prior to treatment, on Day 0 at the completion of the CY infusion, and on Day 3 after finishing clofarabine followed by CY. In brief, peripheral blood and bone marrow blasts were enriched by Ficoll density gradient separation, fixed in 70% ethanol and stored at 4 0 C until staining in TST buffer (TBS, 4% FBS, 0.1% Triton X-100). Cells were incubated in either a 1:500 dilution of anti-phospho-histone H2AX (Upstate Cell Signaling Solutions, Lake Placid, NY), a 1:500 dilution of mouse IgG1 isotype control (SouthernBiotech, Birmingham, AL), or TST alone. After 2 hrs incubation, cells were exposed for 1 hr to a 1:200 dilution of Alexa Fluor® 488 goat antimouse IgG (H+L)(Molecular Probes, Eugene, OR) with 5 µ g/ml RNase, fixed in 2% formaldehyde in TBS, and stored at 4 0 C until flow cytometric analysis. Cellular debris was gated out and non-specific staining controls were used to mark the lower limit of the positive To determine the levels of dATP and dCTP, and the effect of clofarabine on these deoxynucleotides, Ficoll-enriched blasts were extracted with 60% methanol and the dNTPs were quantitated using a modified DNA polymerase assay as described previously 21, 22 .
RESULTS
Patient Demographics
Characteristics of the 18 adults (median age 51, range 27-67) who were enrolled and treated with clofarabine-CY are delineated in Table 1 . All patients had refractory leukemia with multiple poor risk features and had received multiple prior therapies. Median peripheral blood blast count for the entire group was 14 x 10 9 /l (range 0.8 -65), with the median for AML patients being 12 and ALL patients being 29. Of 12 AML patients, 8 (67%) were primary refractory AML, 2 were refractory at second relapse, and 2 had first CR < 6 months. Similarly, 3/6 (50%) ALL had disease recurrence while on maintenance therapy and 2 relapsed after SCT (1 allogeneic, 1 autologous). The majority (14/18, 78%) had adverse cytogenetics [23] [24] [25] , including 10/12 (83%) AML 23,25 and 4/6 (67%) ALL patients (3 complex, 1 Ph+ ALL) 24 . Six patients were treated at dose level 1 (clofarabine 20 mg/m 2 /daily dose, CY 400 mg/m 2 /daily dose) and 12 were treated at dose level 0 (clofarabine 10 mg/m 2 /daily dose, CY 400 mg/m 2 /daily dose). Three of the 12 AML and 3 of the 6 ALL patients received dose level 1, and the remainder (9 AML and 3 ALL) received dose level 0. The decrease in clofarabine dose was prompted by the occurrence of prolonged marrow aplasia (> day 60) in 2 patients (1 AML, 1 ALL) and death in 2 patients from hepatic toxicity and prolonged marrow aplasia (1 ALL) and early onset multi-organ failure (1 AML) ( Table 2 ). These issues are discussed further below in the section on "Toxicities."
Toxicities
The initial dose of CY 200 mg/m 2 on Day 0 induced a pronounced (> 50%) drop in peripheral blasts in only 1 of the 18 patients on study, while 5 patients (3 ALL, 2 AML) had > 20% increases. Following Day 1 clofarabine-CY administration, blast counts fell by > 50% in 12 (67%) patients -5/6 (83%) dose level 1 and 7/12 (58%) dose level 0. By Day 4, following completion of all 3 doses of clofarabine-CY, all patients had a > 50% decrease in peripheral blasts and 15 (83%) had a > 90% decrease. There was no statistical difference noted between the dose levels. Table 3 summarizes the clinical outcome after 1 cycle of clofarabine-CY. Responses occurred at both dose levels. The first response assessment occurred on day 14 of therapy, when marrow was 
Clinical Outcome
DNA Damage
Previous in vitro studies have demonstrated the inability of CLL cells to fully repair CY-induced DNA damage when those cells are pretreated with clofarabine 13 . To determine if clofarabine could have similar effects in vivo, we compared the presence and magnitude of damaged DNA by flow cytometric measurement of γ H2AX in peripheral blood blasts obtained longitudinally from 13 patients prior to Day 0 at end of CY infusion (EOI), and 2 hours after CY EOI, and on Day 1 of clofarabine-CY 2 hours after CY EOI. As depicted in Figure 1 and Table 4 , γ H2AX increased immediately following Day 0 (200 mg/m 2 ) CY in 5 (38%) patients, with > 3-fold For personal use only. on June 15, 2017. by guest www.bloodjournal.org From increases seen in 2 (15%), but did not increase further over the next 2 hours. Administration of clofarabine prior to the Day 1 dose of CY in the same patients, how ever, led to marked increases in γ H2AX relative to Day 0 pretreatment values in 12/13 (92%) patients, with 7/13 (54%) having striking (> 3-fold) increases that persisted for at least 2 hours after the end of the Day 1 CY infusion (Figure 2) . Moreover, cells obtained on Day 1 from 11/13 (85%) patients evinced 
Apoptosis
The overall fraction of peripheral blood blasts undergoing apoptosis, as measured by the amount of sub-2N DNA in the blast population, increased 1.2-to 1.6-fold at all time points relative to Day 0 pretreatment levels ( Table 4) 
Intracellular Clofarabine Metabolism
Clofarabine-TP accumulation was measured at the end of the clofarabine infusion in 4 patients, with intracellular clofarabine-TP levels being 6, 24, 28, and 50 pmoles/10 7 cells. Ribonucleotides 
DISCUSSION
This Phase I trial was designed to test the hypothesis that the administration of clofarabine prior to CY would enhance the DNA damage induced by the alkylating agent and that such prolonged unrerpaired damage, in turn, would lead to increased leukemic cell cytotoxicity 13 , thereby overcoming one potential mechanism of drug resistance in refractory leukemias 26 . Our clinical response and toxicity data and our laboratory studies of the in vivo effects of this drug sequence substantiate this hypothesis. In this highly refractory and heavily pretreated group of adults with For personal use only. on June 15, 2017. by guest www.bloodjournal.org From acute leukemias, a single cycle of clofarabine followed by CY yielded clinical responses in 3/12 (25%) AML patients and 4/6 (67%) ALL patients. The net response rates in this small group of patients do not appear to relate to clofarabine dose. On the other hand, the achievement of Day 14 marrow CTC and CR may relate to the amount of DNA damage achieved with clofarabine-CY, a hypothesis that needs further study in more patients in order to be validated. This notion is consistent with the observation that toxicity was to some extent dose-related, particularly with regard to prolonged marrow aplasia. Nonetheless, there may be some apparent uncoupling of net DNA damage and apoptosis in some patients, particularly those who achieved CTC on Day 14 but ultimately recovered with leukemia (NR). These findings are not surprising and suggest that additional pathways for DNA repair and net cellular survival may be operative in these poor prognosis patients, and may circumvent the enhancement of CY-induced DNA damage by clofarabine.
Clofarabine followed by CY was associated with increases in DNA damage and apoptosis in both AML and ALL blasts from both the peripheral blood and the marrow. The damage was measured by phosphorylation of the histone variant H2AX, an early event that occurs in response to DNA double strand breaks. Data from longitudinal studies conducted in 13 patients suggest an increase in phosphorylation and accumulation of γ H2AX after addition of clofarabine to CY, consistent with the notion that the addition of clofarabine augmented net CYinduced DNA damage. Since this work was performed in a limited number of patients to achieve its Phase I objectives, a more extensive study will be needed to confirm these observations.
The inhibition of DNA synthesis may be due to inhibition of RR and incorporation of clofarabine-TP in the DNA repair patch 20 . In this analysis limited patient sample numbers, we observed no decrease in dATP observed during therapy, which may suggest a limited role of RR For personal use only. on June 15, 2017. by guest www.bloodjournal.org From inhibition. However, in our study, we did not measure the effect of clofarabine on other dNTP pools. In this regard, in vivo studies accompanying a clinical trial of clofarabine given prior to the classical nucleoside analog ara-C detected depletion of intracellular cytosine pools by clofarabine and a resultant increase in ara-CTP incorporation into DNA 6, 8 . The in vivo data recapitulated the in vitro finding that clofarabine potentiated the intracellular metabolism of ara-C in leukemia cell line model systems 27 . In our study, there was a narrow sample range and limited laboratory endpoints, making it difficult to define the total effect of clofarabine on CYinduced DNA damage and any resultant repair response. It will be of interest to examine these parameters in other diseases and in clofarabine combinations with other DNA damaging agents.
Nucleoside analogs such as fludarabine 28, 29 , pentostatin 30 , and cladribine 31, 32 have been combined effectively with CY in lymphoid malignancies such as CLL. Clinical data in patients who failed single agent therapies with either nucleoside analogs or alkylating agents demonstrate that these patients can respond to the combination of such agents with an overall response rate of roughly 40% 33 , suggesting that the combination may lower or eliminate resistance to each agent when used individually.
The combination of clofarabine with the classical alkylating agent CY, which damages DNA directly through adduct formation, is a new combination strategy based on preclinical studies in leukemia cells 20 . At least in theory, this mechanism-based combination requires the presence of clofarabine-TP during the DNA repair phase of CY-induced DNA damage. Thus, an effective combination would be expected to require simultaneous or sequential administration, namely clofarabine followed by CY, in order to afford the presence of clofarabine-TP while the DNA repair machinery is activated 34 .
For personal use only. on June 15, 2017. by guest www.bloodjournal.org From There are several mechanisms which could interplay to create the net enhancement of unrepaired DNA damage. One such mechanism may relate to direct DNA damage from the incorporation of clofarabine-TP into DNA. Further, the high ratio of clofarabine-TP to dATP may serve to enhance the direct CY-related DNA damage. As is true for the clinical responses seen thus far in this patient cohort, the effect of clofarabine on CY-induced DNA damage does not appear to be closely related to the clofarabine dose tested, although only two doses were studied. It may be that the combined effects of clofarabine and CY override any dose-dependent effect of clofarabine alone or that the ability of clofarabine to augment CY-induced DNA damage is independent of dose once sufficient intracellular clofarabine-TP levels are achieved.
In sum, clofarabine followed by CY induces significant leukemia cell kill in patients with refractory AML and ALL on both the molecular and clinical levels. The activity of this combination warrants further exploration in patients with relapsed and refractory acute leukemias. The toxicities of this regimen are noteworthy and suggest that modifications in total doses of one or both drugs may afford equal efficacy while improving tolerability. 
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